In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases.
Biomarker
Dopamine
Molecular connectivity
Substantia nigra
Ventral tegmental area
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
12 11 2021
12 11 2021
Historique:
received:
05
02
2021
accepted:
18
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Preclinical and pathology evidence suggests an involvement of brain dopamine (DA) circuitry in Alzheimer's disease (AD). We in vivo investigated if, when, and in which target regions [123I]FP-CIT-SPECT regional binding and molecular connectivity are damaged along the AD course. We retrospectively selected 16 amyloid-positive subjects with mild cognitive impairment due to AD (AD-MCI), 22 amyloid-positive patients with probable AD dementia (AD-D), and 74 healthy controls, all with available [123I]FP-CIT-SPECT imaging. We tested whether nigrostriatal vs. mesocorticolimbic dopaminergic targets present binding potential loss, via MANCOVA, and alterations in molecular connectivity, via partial correlation analysis. Results were deemed significant at p < 0.05, after Bonferroni correction for multiple comparisons. We found significant reductions of [123I]FP-CIT binding in both AD-MCI and AD-D compared to controls. Binding reductions were prominent in the major targets of the ventrotegmental-mesocorticolimbic pathway, namely the ventral striatum and the hippocampus, in both clinical groups, and in the cingulate gyrus, in patients with dementia only. Within the nigrostriatal projections, only the dorsal caudate nucleus showed reduced [123I]FP-CIT binding, in both groups. Molecular connectivity assessment revealed a widespread loss of inter-connections among subcortical and cortical targets of the mesocorticolimbic network only (poor overlap with the control group as expressed by a Dice coefficient ≤ 0.25) and no alterations of the nigrostriatal network (high overlap with controls, Dice coefficient = 1). Local- and system-level alterations of the mesocorticolimbic dopaminergic circuitry characterize AD, already in prodromal disease phases. These results might foster new therapeutic strategies for AD. The clinical correlates of these findings deserve to be carefully considered within the emergence of both neuropsychiatric symptoms and cognitive deficits.
Sections du résumé
BACKGROUND
Preclinical and pathology evidence suggests an involvement of brain dopamine (DA) circuitry in Alzheimer's disease (AD). We in vivo investigated if, when, and in which target regions [123I]FP-CIT-SPECT regional binding and molecular connectivity are damaged along the AD course.
METHODS
We retrospectively selected 16 amyloid-positive subjects with mild cognitive impairment due to AD (AD-MCI), 22 amyloid-positive patients with probable AD dementia (AD-D), and 74 healthy controls, all with available [123I]FP-CIT-SPECT imaging. We tested whether nigrostriatal vs. mesocorticolimbic dopaminergic targets present binding potential loss, via MANCOVA, and alterations in molecular connectivity, via partial correlation analysis. Results were deemed significant at p < 0.05, after Bonferroni correction for multiple comparisons.
RESULTS
We found significant reductions of [123I]FP-CIT binding in both AD-MCI and AD-D compared to controls. Binding reductions were prominent in the major targets of the ventrotegmental-mesocorticolimbic pathway, namely the ventral striatum and the hippocampus, in both clinical groups, and in the cingulate gyrus, in patients with dementia only. Within the nigrostriatal projections, only the dorsal caudate nucleus showed reduced [123I]FP-CIT binding, in both groups. Molecular connectivity assessment revealed a widespread loss of inter-connections among subcortical and cortical targets of the mesocorticolimbic network only (poor overlap with the control group as expressed by a Dice coefficient ≤ 0.25) and no alterations of the nigrostriatal network (high overlap with controls, Dice coefficient = 1).
CONCLUSION
Local- and system-level alterations of the mesocorticolimbic dopaminergic circuitry characterize AD, already in prodromal disease phases. These results might foster new therapeutic strategies for AD. The clinical correlates of these findings deserve to be carefully considered within the emergence of both neuropsychiatric symptoms and cognitive deficits.
Identifiants
pubmed: 34772450
doi: 10.1186/s13195-021-00925-1
pii: 10.1186/s13195-021-00925-1
pmc: PMC8588696
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Informations de copyright
© 2021. The Author(s).
Références
Acta Neuropathol. 2007 Jan;113(1):53-62
pubmed: 17031655
Ann Neurol. 1995 Mar;37(3):300-12
pubmed: 7695230
Br J Psychiatry. 1980 Jun;136:533-41
pubmed: 6155966
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50
pubmed: 19838702
J Comp Neurol. 1999 Jun 21;409(1):38-56
pubmed: 10363710
Alzheimers Dement (Amst). 2019 Apr 18;11:333-339
pubmed: 31024987
Nature. 2016 Sep 15;537(7620):357-362
pubmed: 27602521
Acta Neuropathol Commun. 2017 Jan 21;5(1):8
pubmed: 28109312
Mov Disord. 1997 Nov;12(6):885-97
pubmed: 9399211
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neuropsychopharmacology. 2010 Jan;35(1):4-26
pubmed: 19812543
J Neurol Sci. 1986 Apr;73(2):219-30
pubmed: 2871136
Brain Res. 2007 Feb 2;1131(1):187-96
pubmed: 17182012
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Neurobiol Aging. 1983 Winter;4(4):261-71
pubmed: 6200784
Neuroimage. 2005 Jul 15;26(4):1150-8
pubmed: 15908232
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1642-1651
pubmed: 31098748
Front Neurosci. 2019 Jun 14;13:617
pubmed: 31258466
Neurology. 2000 Jul 25;55(2):205-9
pubmed: 10908891
Neurology. 2009 Feb 10;72(6):528-34
pubmed: 19204262
Arch Neurol. 1990 Dec;47(12):1318-23
pubmed: 2252449
Nat Commun. 2017 Apr 03;8:14727
pubmed: 28367951
Eur J Neurosci. 2003 Jul;18(1):149-54
pubmed: 12859348
Neuropsychopharmacology. 1987 Dec;1(1):5-15
pubmed: 2908095
PLoS One. 2013 Jul 04;8(7):e68910
pubmed: 23861951
Neurosci Lett. 1996 Jan 12;203(1):29-32
pubmed: 8742039
J Alzheimers Dis. 2020;75(3):1003-1016
pubmed: 32390614
J Alzheimers Dis. 2018;63(1):167-180
pubmed: 29578486
Neurobiol Dis. 2018 Aug;116:142-154
pubmed: 29778899
Mol Imaging Biol. 2016 Apr;18(2):302-12
pubmed: 26341194
Brain Res Bull. 1982 Jul-Dec;9(1-6):321-53
pubmed: 6816390
J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):193-200
pubmed: 2539435
Neurosci Lett. 1993 May 14;154(1-2):171-4
pubmed: 8361636
Alzheimers Dement. 2011 Sep;7(5):532-9
pubmed: 21889116
Clin Neuropathol. 1984 Sep-Oct;3(5):199-205
pubmed: 6499296
J Nucl Med. 1996 Jul;37(7):1129-33
pubmed: 8965183
Neurology. 1998 Jan;50(1):152-6
pubmed: 9443472
Arch Neurol. 2001 Mar;58(3):466-72
pubmed: 11255451
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1938-46
pubmed: 24806112
J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40
pubmed: 9048712
Brain Res. 1988 Dec 13;475(1):164-7
pubmed: 2975188
J Neurol Sci. 1983 Aug-Sep;60(3):383-92
pubmed: 6195313
Neurobiol Aging. 2018 Dec;72:72-82
pubmed: 30237073
Neurology. 1996 Oct;47(4):1065-8
pubmed: 8857746
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Neurobiol Dis. 2018 Sep;117:125-136
pubmed: 29859871
J Neurochem. 1984 Aug;43(2):388-93
pubmed: 6204013
Neurosci Lett. 1984 Nov 23;52(1-2):1-6
pubmed: 6241300
Synapse. 1997 Apr;25(4):345-9
pubmed: 9097393
Neurobiol Aging. 2020 Jan;85:22-37
pubmed: 31734438
J Neural Transm. 1986;65(1):51-62
pubmed: 2870131
Brain Res. 1978 Dec 29;159(2):477-81
pubmed: 215272